NePtune trial (olaparib): what clinicians have said so far
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
- NCT05498272 ↗
- Active, not recruiting
- Rana McKay, MD
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NePtune (olaparib plus goserelin; olaparib plus triptorelin; olaparib plus leuprolide in unfavorable intermediate-risk/high-risk prostate cancer with HRR gene alterations) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NePtune so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations (NePtune)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Prostate Cancer; BRCA1 Mutation; BRCA2 Mutation; Prostatic Adenocarcinoma; High-Risk Cancer
- Interventions
- Olaparib; LHRH agonist
- Arms
- Investigational Group · Experimental
- Enrollment
- 32 (estimated)
- Primary outcomes
- Pathological Complete Response (pCR) rate
- Minimal Residual Disease (MRD) rate
- Sponsor
- Rana McKay, MD with AstraZeneca, University of California, San Diego
- Start
- Feb 1, 2023
- Primary completion
- Aug 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05498272 · updated Jul 10, 2026
Publications
linked from the registry- Montgomery B, Mostaghel EA. Neoadjuvant Therapy Prior to Prostatectomy: Is the Glass Half Full? Eur Urol. 2023 Jun;83(6):519-520. doi: 10.1016/j.eururo.2023.01.021. Epub 2023 Jan 27. No abstract available. PubMed 36710203